Pharma and Life Sciences

Regulatory intelligence began in pharma. The Drug Information Association defines it as "the act of gathering and analyzing publicly available regulatory information," including communicating its implications and monitoring the environment for opportunities to shape future regulation (DIA). Regulators in this sector scan the horizon themselves: the EMA's EU Innovation Network runs a horizon-scanning function for the emerging science and technology that will shape the regulation of human medicines.

For regulatory affairs and intelligence teams, the practical sources are the regulators' own pipelines: FDA draft guidances open for comment, EMA and national competent authority consultations, and the transition deadlines of the EU Medical Device Regulation. This hub collects the guides that apply directly to that work: how regulatory intelligence differs from horizon scanning, what a horizon scanning program looks like, a free horizon scanning register, and the EU AI Act dates that govern AI built into regulated products such as medical devices.